Cingulate Inc.
Cingulate Inc. (Nasdaq: CING) is a biopharmaceutical company developing medicines with its Precision Timed Release drug-delivery platform, which uses erosion barriers to release active ingredients at predetermined intervals in a single tablet. Its pipeline focuses initially on ADHD and anxiety: CTx-1301, a… From the company’s description.
In fiscal 2025, Cingulate Inc. reported a net loss of $22.45M. Operations used $17.25M in cash.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Cingulate Inc. does
In the company’s own words
Cingulate Inc. (Nasdaq: CING) is a biopharmaceutical company developing medicines with its Precision Timed Release drug-delivery platform, which uses erosion barriers to release active ingredients at predetermined intervals in a single tablet. Its pipeline focuses initially on ADHD and anxiety: CTx-1301, a dexmethylphenidate candidate for ADHD, has an FDA application under review, while CTx-1302 is a dextroamphetamine candidate for ADHD and CTx-2103 is a buspirone candidate for anxiety. The company designs its tablets to provide multiple timed doses from one daily administration; it also evaluates other conditions where medicines require repeated daily dosing. Cingulate has no reportable business segments described in the available business information. Its customers are not yet commercial purchasers; its development and potential commercialization activities are aimed at patients, prescribers, healthcare payers and providers. The company’s commercial-stage scale is limited: it reports no product sales in the year ended December 31, 2025. Its website is https://www.cingulate.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- KANSAS CITY, KS
- Fiscal year end
- December
- CIK
- 1862150
- SIC
- 2834
Financial performance, year by year
Fiscal 2021–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Cingulate Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Cingulate Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Cingulate Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Cingulate Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Cingulate Inc.'s last four quarterly filings that the numbers alone won't show?”